Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

intervet international bv - live myxom-vektoriserede kanin hæmorrhagi virus stamme 009 - immunologiske - kaniner - til aktiv immunisering af kaniner fra fem ugers alder og fremefter for at reducere dødelighed og kliniske tegn på myxomatose og for at forhindre dødelighed på grund af kanin hæmoragisk sygdom. immunitetens begyndelse: 3 uger. immunitetens varighed: 1 år.

Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - felint calicivirus (fcv), stamme f9 (levende, svækket), felint panleukopenivirus (fplv), stamme mw-1 (levende, svækket), felint rhinotracheitisvirus (fvr), stamme fvrm (levende, svækket) - lyofilisat og solvens til injektionsvæske, suspension

Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - bordetella bronchiseptica bakterie, stamme b-c2 (levende), canine parainfluenzavirus (cpiv), stamme cornell (levende, svækket) - lyofilisat og solvens, suspension til nasal administration

Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - levende felin panleucopenia virus / parvovirus + levende felin bovis virus + levende felin calicivirus + inaktiveret felin leukæmi virus - katte - til aktiv immunisering af katte fra otte uger mod: feline calicivirosis for at reducere kliniske tegn. feline viral rhinotracheitis for at reducere kliniske tegn og viral udskillelse. feline panleucopeni for at forhindre leukopeni og reducere kliniske tegn. feline leukæmi for at forhindre vedvarende viraemia og kliniske tegn på den relaterede sygdom. immunitetens begyndelse: 3 uger efter den primære vaccination for panleucopeni og leukæmikomponenterne og 4 uger efter den primære vaccination for calicivirus- og rhinotracheitisviruskomponenterne. immunitetens varighed: et år efter den primære vaccination for alle komponenter.

Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinant tyrkiet herpesvirus, stamme vhvt013-69, live - immunologicals for aves, tamhøns, immunologicals - embryonated eggs; chicken - til aktiv immunisering af kyllinger:for at forhindre dødelighed og til at reducere kliniske tegn og læsioner af infectious bursal disease. for at reducere dødeligheden, kliniske tegn og læsioner af marek ' s disease.

Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vacciner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. brug af dengvaxia bør være i overensstemmelse med de officielle anbefalinger.

Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - bovin respiratorisk syncytial (brsv) virus (levende) mangler angivelse af stamme, bovint parainfluenzavirus 3 (levende, svækket), mangler information stamme - næsespray, lyofilisat og solvens til suspension

Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, stamme cvd-103-hgr, live - kolera - vacciner - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. denne vaccine bør anvendes i overensstemmelse med officielle anbefalinger.

Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologicals for aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kylling - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.